Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 5Radiotherapy 4Radiation 3Radiotherapy, Conformal 2Platinum 2Pemetrexed 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Immunoglobulin G 2Disulfides 2Cisplatin 2Bevacizumab 21,2-diaminocyclohexaneplatinum II citrate 2veliparib 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1methoxyamine 1lazertinib 1durvalumab 1capmatinib 1Taxes 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Nivolumab 1Metformin 1Ipilimumab 1Granulocyte Colony-Stimulating Factor 1Gefitinib 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × methoxyamine × 30 days × Clear all
NCT05198830 2026-05-27

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
42 enrolled
Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡